Back to discover

Protein / target

Oxytocin receptor

Encoded byOXTRP30559Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
4
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Vasopressin receptor

Strongest disease association

Postpartum hemorrhage

Via encoding gene OXTR · Clinical evidence · score 0.55

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the posterior pituitary gland that plays a key role in social behavior and other biological processes, such as milk ejection.

View complete UniProt function annotation

G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the posterior pituitary gland that plays a key role in social behavior and other biological processes, such as milk ejection (PubMed:11923477, PubMed:22069312, PubMed:32832646, PubMed:35104164, PubMed:35241813, PubMed:35851571). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as phospholipase C (PubMed:22069312, PubMed:32832646, PubMed:35104164, PubMed:35241813, PubMed:35851571). OXTR is mainly coupled to G(q) G proteins and mediates production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively (PubMed:11923477, PubMed:22069312, PubMed:32832646, PubMed:35104164, PubMed:35241813, PubMed:35851571). In presence of high levels of oxytocin, also coupled to G(i) G proteins, mediating inhibition of adenylate cyclase activity (PubMed:22069312, PubMed:35241813, PubMed:35851571). Central release of oxytocin plays essential roles in social behavior, such as maternal care, social cognition and affiliative behaviors, triggering signaling that modulates neural circuits by altering ion channel activity, changing intrinsic neuronal properties and modifying synaptic transmission (both excitatory and inhibitory) (PubMed:19934046, PubMed:20647384, PubMed:21896752, PubMed:22123970, PubMed:24367110). Peripheral release of oxytocin (secretion into the bloodstream) promotes various processes, such as parturition, lactation or osteoblast differentiation (PubMed:6278592). OXTR-mediated signaling promotes milk ejection by triggering and strengthening contraction of the smooth muscle of mammary gland (By similarity)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (13)

Gene Ontology

  • Cplasma membrane
  • Foxytocin receptor activity
  • Fvasopressin receptor activity
  • Pcell surface receptor signaling pathway
  • Pcellular response to hormone stimulus
  • Pfemale pregnancy
  • PG protein-coupled receptor signaling pathway
  • Plactation
  • Pmaternal process involved in parturition
  • Pmuscle contraction
  • Ppositive regulation of cold-induced thermogenesis
  • Ppositive regulation of vasoconstriction

389 aa · 43 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingUniProtIon channel gatingUniProtG protein-coupled signallingUniProt · GO
View supporting evidence

Synaptic signalling

  • ·G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the po…

Ion channel gating

  • ·G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the po…

G protein-coupled signalling

  • ·G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the po…
  • ·G protein-coupled receptor signaling pathway
View underlying pathways (2)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

OXTGNAQGNASAVPGNAI3GNAI1GNAI2GNB1GNG2DRD2OXTR

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 1 area

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Hemorrhage1 medicine

4 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Oxytocin
Narrow target profileApprovedAgonist

Oxytocin receptor agonist

Indicated for Hemorrhage

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene OXTR

Gene-level evidence surfaced through the gene OXTRthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Postpartum hemorrhage
0.69Moderately supported

Clinical evidence dominant · Open Targets 0.55

Autism Spectrum Disorder
0.66Moderately supported

Clinical evidence dominant · Open Targets 0.53

Prader-Willi syndrome
0.49Limited support

Clinical evidence dominant · Open Targets 0.38

Uterine Inertia
0.48Limited support

Clinical evidence dominant · Open Targets 0.39

Alcoholism
0.48Limited support

Clinical evidence dominant · Open Targets 0.37

View evidence synthesis (5)
Postpartum hemorrhageModerately supported
0.69
agreement 0.530.84
Clinical98%Literature2%

Open Targets aggregate 0.55 · 2 independent evidence families

Autism Spectrum DisorderModerately supported
0.66
agreement 0.510.82
Clinical95%Literature5%

Open Targets aggregate 0.53 · 2 independent evidence families

Prader-Willi syndromeLimited support
0.49
agreement 0.330.64
Clinical87%Literature13%

Open Targets aggregate 0.38 · 2 independent evidence families

Uterine InertiaLimited support
0.48
agreement 0.330.64
Clinical99%Literature1%

Open Targets aggregate 0.39 · 2 independent evidence families

AlcoholismLimited support
0.48
agreement 0.330.64
Clinical87%Literature13%

Open Targets aggregate 0.37 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Postpartum hemorrhage0.55
Autism Spectrum Disorder0.53
Neurodegenerative Diseases0.39
Uterine Inertia0.39
Prader-Willi syndrome0.38
Alcoholism0.37

Drug development

9 compounds recorded · 4 approved · 5 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (9)
BARUSIBANPhase 2
ATOSIBANApproval
RETOSIBANPhase 3
EPELSIBANPhase 2
CARBETOCINApproval
FE 202767Phase 2
NOLASIBANPhase 3
OXYTOCINApproval
ATOSIBAN ACETATEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Advanced Clinical and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (10)
SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Small Molecule BinderOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via Oxytocin · NCT06334172

COMPLETED · via Oxytocin · NCT03899961

UNKNOWN · via Oxytocin · NCT03937401

COMPLETED · via Oxytocin · NCT03308643

COMPLETED · via Oxytocin · NCT02595749

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. New publication2025-07-22
    G Proteins-Associated Dose-Dependent Effects of Oxytocin on Oxytocin Neuronal Activity and Astrocytic Plasticity of the Supraoptic Nucleus.

    Molecular neurobiology · 2025 · 1 citation · Europe PMC · via Oxytocin

  2. New publication2024-05-03
    Oxytocin and corticotropin-releasing hormone exaggerate nucleus tractus solitarii neuronal and synaptic activity following chronic intermittent hypoxia.

    The Journal of physiology · 2024 · 4 citations · Europe PMC · via Oxytocin

  3. New publication2024-04-11
    Convergence of oxytocin and dopamine signalling in neuronal circuits: Insights into the neurobiology of social interactions across species.

    Neuroscience and biobehavioral reviews · 2024 · 29 citations · Europe PMC · via Oxytocin

  4. New publication2023-12-26
    Social anxiety disorder-associated gut microbiota increases social fear.

    Proceedings of the National Academy of Sciences of the United States of America · 2024 · 52 citations · Europe PMC · via Oxytocin

  5. New publication2023-06-14
    Psychedelics reopen the social reward learning critical period.

    Nature · 2023 · 227 citations · Europe PMC · via Oxytocin

  6. New publication2021-09-30
    A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome.

    Molecular autism · 2021 · 17 citations · Europe PMC · via Oxytocin

  7. New publication2021-04-06
    Oxytocin, Neural Plasticity, and Social Behavior.

    Annual review of neuroscience · 2021 · 339 citations · Europe PMC · via Oxytocin

  8. New publication2013-05-12
    Effects of single dose intranasal oxytocin on social cognition in schizophrenia.

    Schizophrenia research · 2013 · 93 citations · Europe PMC · via Oxytocin

  9. New publication2011-12-14
    Cervical ripening with foley balloon plus fixed versus incremental low-dose oxytocin: a randomized controlled trial.

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2012 · 8 citations · Europe PMC · via Oxytocin

  10. New publication2009-05-01
    Concurrent dinoprostone and oxytocin for labor induction in term premature rupture of membranes: a randomized controlled trial.

    Obstetrics and gynecology · 2009 · 14 citations · Europe PMC · via Oxytocin

  11. New publication2006-05-01
    A prospective randomized study comparing misoprostol and oxytocin for premature rupture of membranes at term.

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2006 · 16 citations · Europe PMC · via Oxytocin

  12. New publication1996-04-01
    Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group.

    The New England journal of medicine · 1996 · 253 citations · Europe PMC · via Oxytocin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Related literature

1

Papers indexed under “Receptors, Oxytocin” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.

Oxytocin, Neural Plasticity, and Social Behavior.

Froemke RC · Annual review of neuroscience · 2021

Europe PMC literature, reached through a MeSH descriptor linked to this protein.